I

Intuitive Surgical

Builds robots for minimally invasive surgery

Regulatory Operations Specialist

Full-TimeUpdated
$88.9k - $141.5k+ Incentives + Equity
Mid, Senior
Bachelor's, Master's
Sunnyvale, CA, USA
HybridHybrid schedule: 3 days onsite and 2 days remote in Sunnyvale. Residence preference excludes 14 listed states.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Some relevant experience working in a medical device company; 1–2 years of experience in regulatory operations or software development is preferred.
  • Knowledge of the essentials of data structures and algorithms, software design, and architecture.
  • Strong attention to detail and ability to follow procedures, processes, and instructions.
  • Good written and oral communication and organizational skills.
  • Ability to perform multiple tasks in a fast-paced environment.
  • Motivation to excel and work in a team environment.
  • Excellent customer service and interpersonal skills.
  • Ability to deal with problems and issues professionally.
  • Ability to understand the implications of work and make recommendations for process improvements.
  • Excellent skills in Microsoft Word, Excel, and Outlook, and capacity to learn additional software.
  • Ability to identify and solve basic problems.
  • Required education: bachelor's degree in science (biology, chemistry, microbiology, immunology, medical technology, pharmacy, pharmacology, biomedical engineering), math, engineering, or medical fields with 4–5 years’ experience; or a master's degree or foreign equivalent in biomedical engineering, regulatory science, life science, pharmacy, or a related field with 1–2 years’ experience.
Responsibilities
  • Provide regulatory and operational support for new-country product launches, global new-site registrations, and site renewals for company and third-party sites.
  • Prepare standardized technical documentation for medical devices for use across global submissions.
  • Assist with facility transfers and manufacturing-line transfer projects.
  • Communicate cross-functionally with corporate and global departments to improve regulatory tools and corporate processes that may affect or relate to regulatory work.
  • Draft and update regulatory department procedures and work-process tools, including templates, forms, standard operating procedures, work instructions, checklists, and trackers, to promote efficiency and productivity.
  • Review procedures and identify process improvements based on data and user experience.
  • Collaborate with development teams to help design tools and applications for regulatory processes and workflows.
  • Support the audit team by preparing documents for use in audits.
Desired Qualifications
  • Experience writing technical specifications, user requirements, and functional requirements is preferred but not required.
  • Strong attention to detail and ability to follow procedures, processes, and instructions.
  • Ability to understand the implications of work and make recommendations for process improvements.
  • Excellent skills in Microsoft Word, Excel, and Outlook, and capacity to learn additional software.
  • Good written and oral communication and organizational skills.
  • Ability to perform multiple tasks in a fast-paced environment.
  • Motivation to excel and work in a team environment.
  • Knowledge of the essentials of data structures and algorithms, software design, and architecture.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 28th, 2026
Intuitive Surgical at $445.88: 36% overvalued by one model, undervalued by another

Intuitive Surgical's latest earnings showed higher quarterly revenue but lower net income and earnings per share. Its shares trade at $445.88, up 26.32% over 90 days and 7.50% over 30 days. Over longer periods the picture is weaker. The stock is down 20.66% this year, and one-year total shareholder return is down 17.06%. Valuation views differ. One community narrative puts fair value at $327.67, making the shares 36% overvalued. It assumes 14.7% annual revenue growth and a 25% long-term net profit margin, against 28.45% now. A Simply Wall St discounted cash flow model estimates value at $468.27, which suggests the shares are 4.8% undervalued.

Yahoo Finance
Oct 26th, 2026
Intuitive Surgical trades at 40x earnings, but forecast profit of $4.55B in 2027 cuts it to 34.7x

Intuitive Surgical (ISRG), maker of da Vinci surgical robots, trades at 40.0 times adjusted earnings over the last twelve months. Against forecast profit, the multiple looks lower: its $158 billion market value is 39.5 times expected fiscal 2026 net income of $3.99 billion, and 34.7 times fiscal 2027 net income of $4.55 billion. Consensus puts fiscal 2027 revenue at $13.3 billion, up 12.1%, slower than the 20.5% growth of the last twelve months. The forecast net margin of 34.1% is close to the 34% the company kept over that period. Risks include instrument pricing cuts of about 3% to 5% per procedure and higher spending. Management will give operating expense guidance in January.

LinkedIn
Oct 25th, 2026
Ruby Robotics Acquired by Intuitive for Minimally Invasive Care Solutions | Ruby Robotics posted on the topic | LinkedIn

We are excited to announce that in late 2025, Ruby Robotics was acquired by Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.   Together with Intuitive, we are continuing our mission to improve the accuracy, efficiency, and accessibility of tissue assessment during biopsy procedures at the point of care with integrated robotics and artificial intelligence solutions.   Thank you to our team, investors, advisors, consultants, and contributors whose shared belief in our vision made Ruby a success. To our new Intuitive colleagues: we’re excited to collaborate with you and look forward to making a positive impact on patients and physicians together. E14 Fund Root Ventures Link Ventures SeedFolio Kicker Ventures Celtic House Asia Partners Zelda Ventures Tamer Capital Taiwan Global Angels Cendana Capital UNION | 19 comments on LinkedIn

Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.